Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer: Translating Evidence to Clinical Practice - Episode 5

Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib

, ,

Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.